Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism.
Acute psychiatric illness may be accompanied by transient hyperthyroxinemia. The mechanism of this phenomenon was examined by determining the role of thyrotropin (TSH) in the genesis of this state. Serial measurements of TSH, thyroxine (T4), free T4 index (FT4I), triiodothyronine (T3), and free T3 index (FT3I) were performed in 45 acutely hospitalized patients with major psychiatric disorders. Twenty-two (49%) patients exhibited significant elevations (greater than or equal to 2 SD above mean value of controls) of one or more thyroid hormone (or index) levels. Among depressed patients with elevated FT4I, TSH was higher (p less than .05) on the day of the peak FT4I than on the day of the FT4I nadir. There were significant positive correlations between psychiatric symptom severity and levels of FT4I among both depressed (p less than .01) and schizophrenic (p less than .025) patients. These data show that elevations of T4, FT4I, T3, and FT3I are common among psychiatric inpatients, especially early in their hospitalization, and that levels of thyroid hormones are correlated with severity of psychiatric symptomatology. TSH is higher early in the acute phase of illness and is not suppressed in the face of elevated thyroid hormone levels, a finding that distinguishes this phenomenon from ordinary hyperthyroidism. Elevations of peripheral thyroid hormone levels, particularly among depressed patients, may result from a centrally-mediated hypersecretion of TSH.
Roca
R P
RP
Department of Psychiatry, Francis Scott Key Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224.
Blackman
M R
MR
Ackerley
M B
MB
Harman
S M
SM
Gregerman
R I
RI
D000328:Adult; D001714:Bipolar Disorder / Q000188:drug therapy / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology; D003866:Depressive Disorder / Q000378:metabolism; D015536:Down-Regulation; D005246:Feedback; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D006980:Hyperthyroidism / Q000175:diagnosis*; D008094:Lithium / Q000494:pharmacology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009661:Nortriptyline / Q000627:therapeutic use; D010259:Paranoid Disorders / Q000188:drug therapy / Q000378:metabolism; D011446:Prospective Studies; D011618:Psychotic Disorders / Q000503:physiopathology*; D011863:Radioimmunoassay; D012044:Regression Analysis; D012559:Schizophrenia / Q000503:physiopathology; D013963:Thyroid Hormones / Q000097:blood*; D013972:Thyrotropin / Q000502:physiology*; D013974:Thyroxine / Q000097:blood; D013975:Thyroxine-Binding Proteins / Q000096:biosynthesis; D014284:Triiodothyronine / Q000096:biosynthesis
D013963:Thyroid Hormones; D013975:Thyroxine-Binding Proteins; D014284:Triiodothyronine; D013972:Thyrotropin; D008094:Lithium; D009661:Nortriptyline; D006220:Haloperidol; D013974:Thyroxine